IXICO secures additional Huntington’s disease contracts
IXICO plc, the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Huntington’s disease (HD) clinical trials.READ MORE
Alzheimer's Association International Conference (AAIC) Poster 2020
Regional differences of Amyloid PET SUVR induced by spatial smoothing and the role of reference regionREAD MORE
Going for growth: IXICO primed to solve the challenge of increased clinical trial complexity through AI advances
Article written by ShareBuyers Editorial Team originally published here As part of the ShareBuyers’ going for growth series, we take a look into the growth prospects of IXICO (IXI), the AIM-listed specialist in AI data analysis for the international clinical trial market which has seen its share price increase by 80% over the past six months....READ MORE
HSG 2020: HD IN FOCUS
The Huntington Study Group’s renowned annual event, HSG 2020: HD in Focus: Navigating HD, will bring together more than 600 of the world’s leading Huntington disease (HD) researchers, health care providers, industry representatives, and members of the HD community to provide a forum for training and education in Huntington disease (HD) and for presentation of...READ MORE
Head of ITREAD MORE
IXICO has extensive experience in supporting regulatory-compliant clinical research, working with clients on the selection and use of neuroimaging and digital biomarkers - whether directly with your teams or as part of collaborative consortia.Read more
We have extensive experience in definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.
IXICO's global network of over 2,000 imaging sites across 75 countries and bespoke TrialTracker platform ensure that large-scale trials can be set up quickly and efficiently to deliver data that is as reliable as it is regulatory compliant.Read more
IXICO understands the challenges of extended longitudinal studies, and the importance of monitoring patient safety and drug utilization for ongoing optimization of patient pathways post marketing.Read more
IXICO has supported important Alzheimer's Disease research since 2007 and continues to assist many pharmaceutical companies in their search for novel therapies. We have provided both MRI and PET imaging biomarkers for over 70 clinical studies in neuroscience, of which, over 30 have been in Alzheimer's disease.Read more
IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.Read more
IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.Read more
We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.Read more
Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.Read more
IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).Read more
IXICO is developing and validating new machine learning algorithms to analyse wearable biosensor data for specific neurodegenerative diseases. These disease-specific algorithms can improve the sensitivity and specificity of standard algorithms to measure physiological parameters such as sleep, activity and circadian rhythm.
IXICO's compliant image and digital data management, provides all you need to manage the complex data workflows that come with many clinical trials. IXICO also offers a secure online digital platform as an enabler of clinical decision support for patient selection and post-marketing surveillance.